Santiago, Chile – On May 17, 2024, MicroPort^® CardioFlow Medtech Corporation(" MicroPort^® CardioFlow ", 02160.HK ) completed the first implantation with its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^® ) at the Sótero del Río Hospital in Chile. Dr. Martín Valdebenito, the director of cardiology at the hospital, and Dr. Juan Pablo De Brahi, a renowned Argentine cardiologist, performed the procedure and successfully treated a patient with severe aortic valve stenosis, with no conduction blocks or paravalvular leaks occurring and the transvalvular pressure gradient dropped to 4mmHg postoperatively. The patient was discharged within three days after the successful implantation.

Shanghai, China，03 June , 2024 — Recently, AltaValve™, a transcatheter mitral valve replacement (TMVR) system developed by 4C Medical, has been granted two Breakthrough Device designations by the Food and Drug Administration (FDA). These designations specifically target treatment indications for moderate to severe or severe mitral regurgitation (MR) and moderate/severe MR with moderate/severe mitral annular calcification.

SHANGHAI, June 17, 2024 /PRNewswire/ -- MicroPort^® CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) recently announced that its self-developed second-generation transcatheter aortic valve implantation (TAVI) device, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), has received EU CE-MDR certification. This certification highlights VitaFlow Liberty^® as a pioneering TAVI solution, that sets a new benchmark in transcatheter heart valve treatments.